May 14, 2012 11:39 AM | 1 min read
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
In a company update published earlier today, Citigroup Inc. maintained its Buy rating for Medtronic, Inc. (NYSE: MDT) and slightly lowered its price target from $48.00 to $47.00.Citigroup went on to say “Medtronic's relative price-to-earnings (P/E) multiple to its large-cap med tech peers is at a 20% discount, versus a ten-year average of a 15% premium. Medtronic looks poised to recapture some of its historical multiple premium behind a new product pipeline that is starting to roll out and should gain traction in the coming quarters. Short term, challenging markets in ICDs, stents, and spinal implants should offset some of the pipeline gains and we now expect Medtronic's ability to outgrow its peers to take a year longer and start in F2013.”Medtronic, Inc. closed yesterday at $38.03.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.